Late Breaking Abstract - Value of the interleukin profile can be an objective standart for control  the tactics of managing patients with bronchiolitis

P. Berezhanskiy (Moscow, Russian Federation), A. Andjel (Moscow, Russian Federation), A. Malachov (Moscow, Russian Federation), V. Elagina (Moscow, Russian Federation)

Source: Virtual Congress 2021 – Respiratory infections
Session: Respiratory infections
Session type: Oral Presentation
Number: 1660

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Berezhanskiy (Moscow, Russian Federation), A. Andjel (Moscow, Russian Federation), A. Malachov (Moscow, Russian Federation), V. Elagina (Moscow, Russian Federation). Late Breaking Abstract - Value of the interleukin profile can be an objective standart for control  the tactics of managing patients with bronchiolitis. 1660

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Late Breaking Abstract - Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia
Source: Virtual Congress 2021 – Diagnosis and management of COVID-19
Year: 2021


Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019




Late Breaking Abstract - Use of mepolizumab in bronchiectasis with underlying eosinophilic condition
Source: International Congress 2018 – New methods for diagnosing and treating lung diseases
Year: 2018



Late Breaking Abstract - Defining a severe asthma super-responder: findings from a Delphi process
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020


Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018



Late Breaking Abstract - Evaluating the feasibility, safety, and efficacy of senolytics in idiopathic pulmonary fibrosis
Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Year: 2019



Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021


Late Breaking Abstract - Comparative analysis of effectiveness of Asthma Control Test-guided treatment versus usual care in patients with asthma from China
Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Year: 2020


Late Breaking Abstract - Determinants of disease control in patients with severe COPD. The CLAVE Study
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019


Late Breaking Abstract - Promising results of the infliximab biosimilar Inflectra® in severe sarcoidosis patients
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017


Late Breaking Abstract - Capnography for ultimately simple diagnostics of COPD
Source: International Congress 2017 – Innovation in COPD: techniques and facts
Year: 2017



Late Breaking Abstract - Use of a simple telecoaching pulmonary rehabilitation protocol for COPD patients.
Source: International Congress 2019 – Breathing, posture and physical activity in respiratory disease patients
Year: 2019


Late Breaking Abstract - Comparative real world effectiveness of triple therapy versus dual bronchodilation in frequently exacerbating patients with COPD
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018


Late Breaking Abstract - Effects of pulmonary rehabilitation on major symptoms of long COVID (post-COVID-19 syndrome): preliminary results
Source: Virtual Congress 2021 – A multidisciplinary approach to pulmonary rehabilitation and management of chronic respiratory diseases
Year: 2021


Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy.
Source: International Congress 2018 – New pharmacological strategies in airway diseases
Year: 2018



Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Year: 2020




Late Breaking Abstract - Lung ultrasound for severity assessment and outcome prediction of COVID-19 patients.
Source: Virtual Congress 2020 – Transthoracic and endobronchial ultrasound
Year: 2020


Late Breaking Abstract - Lung function tests in patients with previous SARS-COV2 pneumonia: a useful follow-up tool
Source: Virtual Congress 2021 – Exacerbations of chronic respiratory diseases, including SARS-CoV-2
Year: 2021



Late Breaking Abstract - Overlap of SGRQ and CAT-defined chronic mucus hypersecretion in the SPIROMICS cohort: implications for digital health
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018

Late Breaking Abstract - iPREDICT: Pilot study to develop predictive model of changes in asthma control
Source: International Congress 2019 – Lung function evaluation and prognosis of airway diseases
Year: 2019